• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

    5.740 -0.100 (-1.71%)
    Streaming Delayed Price Updated: 10:19 AM EDT, Oct 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 163,142
    Open 5.820
    Bid (Size) 5.740 (3)
    Ask (Size) 5.750 (8)
    Prev. Close 5.840
    Today's Range 5.710 - 5.890
    52wk Range 5.680 - 17.98
    Shares Outstanding 42,734,644
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics to Participate in Upcoming Investor Conferences
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -53.7%
    -53.7%
    1 Month
    -16.1%
    -16.1%
    3 Month
    -22.6%
    -22.6%
    6 Month
    -20.8%
    -20.8%
    1 Year
    -64.2%
    -64.2%

    More News

    Read More
    Cullinan (CGEM) Q2 R&D Jumps 68%
    Via The Motley Fool
    CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Reports Wider Q2 2025 Loss, Misses EPS Estimates Amid Rising R&D Costs
    Via Chartmill
    Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix
    Via Stocktwits
    Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
    From Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Applied Digital Posts Weak Revenue, Joins Allegro MicroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics to Participate in Upcoming Investor Conferences
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Cullinan Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Cullinan Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Cullinan Therapeutics, Inc. - Common Stock trade on?
    Cullinan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cullinan Therapeutics, Inc. - Common Stock?
    The ticker symbol for Cullinan Therapeutics, Inc. - Common Stock is CGEM on the Nasdaq Stock Market
    What is the current price of Cullinan Therapeutics, Inc. - Common Stock?
    The current price of Cullinan Therapeutics, Inc. - Common Stock is 5.740
    When was Cullinan Therapeutics, Inc. - Common Stock last traded?
    The last trade of Cullinan Therapeutics, Inc. - Common Stock was at 10/07/25 10:19 AM ET
    What is the market capitalization of Cullinan Therapeutics, Inc. - Common Stock?
    The market capitalization of Cullinan Therapeutics, Inc. - Common Stock is 245.30M
    How many shares of Cullinan Therapeutics, Inc. - Common Stock are outstanding?
    Cullinan Therapeutics, Inc. - Common Stock has 245M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.